Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of YHI-1003 (perifosine) monotherapy in advanced or relapsed gynecologic cancer
jRCT2080222238Phase 2
- Sponsor
- Yakult Honsha
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perifosine in ovarian cancer, endometrial cancer (EC) and Cervical Cancer (CC), sponsored by Yakult Honsha.
02
Drugs
perifosine
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2080222238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222238.